MX2020005944A - Analogos espirobiciclicos novedosos. - Google Patents

Analogos espirobiciclicos novedosos.

Info

Publication number
MX2020005944A
MX2020005944A MX2020005944A MX2020005944A MX2020005944A MX 2020005944 A MX2020005944 A MX 2020005944A MX 2020005944 A MX2020005944 A MX 2020005944A MX 2020005944 A MX2020005944 A MX 2020005944A MX 2020005944 A MX2020005944 A MX 2020005944A
Authority
MX
Mexico
Prior art keywords
spirobicyclic
analogues
novel
compounds
present
Prior art date
Application number
MX2020005944A
Other languages
English (en)
Inventor
Lieven Meerpoel
Dirk Brehmer
Vineet Pande
Weimei Sun
Tongfei Wu
Jonas Verhoeven
Guido Alfons F Verniest
Johannes Wilhelmus John F Thuring
Scott E Denmark
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020005944A publication Critical patent/MX2020005944A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a análogos espirobicíclicos novedosos de fórmula (ver fórmula I) en donde las variables tienen el significado definido en las reivindicaciones. Los compuestos de acuerdo con la presente invención son útiles como inhibidores PRMT5; la invención se refiere además a composiciones farmacéuticas que comprenden dichos compuestos como principio activo, así como también al uso de dichos compuestos como un medicamento.
MX2020005944A 2017-12-08 2018-12-06 Analogos espirobiciclicos novedosos. MX2020005944A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762596441P 2017-12-08 2017-12-08
EP18163867 2018-03-26
PCT/EP2018/083808 WO2019110734A1 (en) 2017-12-08 2018-12-06 Novel spirobicyclic analogues

Publications (1)

Publication Number Publication Date
MX2020005944A true MX2020005944A (es) 2020-08-24

Family

ID=64664279

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005944A MX2020005944A (es) 2017-12-08 2018-12-06 Analogos espirobiciclicos novedosos.

Country Status (13)

Country Link
US (3) US11059850B2 (es)
EP (2) EP3720865B1 (es)
JP (1) JP7352544B2 (es)
KR (1) KR20200097280A (es)
CN (1) CN111479817B (es)
AU (1) AU2018379456B2 (es)
BR (1) BR112020010815A2 (es)
CA (1) CA3084449A1 (es)
ES (1) ES2978117T3 (es)
IL (1) IL275129B2 (es)
MA (1) MA51004A (es)
MX (1) MX2020005944A (es)
WO (1) WO2019110734A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
KR102531344B1 (ko) 2016-10-03 2023-05-10 얀센 파마슈티카 엔.브이. Prmt5 억제제로서 사용하기 위한 신규의 모노사이클릭 및 바이사이클릭 고리 시스템 치환된 카르바뉴클레오시드 유사체
CA3049739A1 (en) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
JP7352544B2 (ja) * 2017-12-08 2023-09-28 ヤンセン ファーマシューティカ エヌ．ベー． 新規なスピロ二環式類似体
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
SG11202110272SA (en) 2019-03-25 2021-10-28 California Inst Of Techn Prmt5 inhibitors and uses thereof
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
IL288741B2 (en) * 2019-06-12 2025-03-01 Janssen Pharmaceutica Nv Novel spirobicyclic intermediates
WO2021086879A1 (en) 2019-10-28 2021-05-06 Tango Therapeutics, Inc. Compounds and methods of use
EP4087576A1 (en) * 2020-01-07 2022-11-16 Pfizer Inc. Prmt5 inhibitor for use in a method of treating psoriasis and other autoimmune conditions
EP4188920A1 (en) 2020-07-31 2023-06-07 Tango Therapeutics, Inc. Piperidin-1-yl-n-pyrydine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
WO2026008533A1 (en) 2024-07-01 2026-01-08 Janssen Pharmaceutica Nv Prmt5 inhibitors for treating adenomas

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
WO1998040686A1 (de) * 1997-03-13 1998-09-17 Peter Spielberger Holster für handfeuerwaffen
CN1331326A (zh) 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人精氨酸甲基转移酶(hrmt)32.12和编码这种多肽的多核苷酸
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
CA2476683C (en) 2002-02-19 2011-11-01 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
WO2005005450A1 (ja) 2003-07-15 2005-01-20 Mitsui Chemicals, Inc. 環状ビスジヌクレオシドの合成方法
JP2007537999A (ja) 2003-12-19 2007-12-27 コローニス ファーマシューティカルズ インコーポレイテッド 変異原性複素環
EP1844062A2 (en) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibitors of dna methyltransferase
US20110159111A1 (en) 2006-06-29 2011-06-30 Astex Therapeutics Limited Pharmaceutical combinations
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
EP2342616A2 (en) 2008-09-23 2011-07-13 Alnylam Pharmaceuticals Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
US8323918B2 (en) 2008-12-12 2012-12-04 University Of South Carolina Chloroacetamidine based inhibitors and activity based probes for the protein arginine methytransferases
SG181703A1 (en) 2009-12-18 2012-07-30 Harvard College Beta-cell replication promoting compounds and methods of their use
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
CA2819620A1 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
AU2011336272A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
JP5906253B2 (ja) 2010-12-16 2016-04-20 アッヴィ・インコーポレイテッド 抗ウイルス性化合物
US9284343B2 (en) 2011-04-04 2016-03-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides
US20140357594A1 (en) 2011-10-24 2014-12-04 Glaxosmithkline Intellectual Property (No.2) Limited New compounds
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100716A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US8993555B2 (en) 2012-12-21 2015-03-31 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
JP6510485B2 (ja) 2013-03-15 2019-05-08 オハイオ・ステイト・イノベーション・ファウンデーション Ｐｒｍｔ５インヒビターおよびそれらの使用方法
WO2015106025A1 (en) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
HUE045748T2 (hu) 2014-07-01 2020-01-28 Millennium Pharm Inc Heteroaril vegyületek mint SUMO aktiváló enzimek inhibitorai
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
PE20181894A1 (es) * 2016-03-10 2018-12-11 Janssen Pharmaceutica Nv Nuevos analogos de nucleosidos sustituidos para su uso como inhibidores de prmt 5
KR102531344B1 (ko) 2016-10-03 2023-05-10 얀센 파마슈티카 엔.브이. Prmt5 억제제로서 사용하기 위한 신규의 모노사이클릭 및 바이사이클릭 고리 시스템 치환된 카르바뉴클레오시드 유사체
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
CA3049739A1 (en) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
JP7352544B2 (ja) * 2017-12-08 2023-09-28 ヤンセン ファーマシューティカ エヌ．ベー． 新規なスピロ二環式類似体

Also Published As

Publication number Publication date
EP3720865A1 (en) 2020-10-14
RU2020122212A (ru) 2022-01-10
CA3084449A1 (en) 2019-06-13
WO2019110734A1 (en) 2019-06-13
MA51004A (fr) 2020-10-14
US11702441B2 (en) 2023-07-18
US20210380627A1 (en) 2021-12-09
US12145961B2 (en) 2024-11-19
IL275129B2 (en) 2023-10-01
US11059850B2 (en) 2021-07-13
US20230303612A1 (en) 2023-09-28
ES2978117T3 (es) 2024-09-05
KR20200097280A (ko) 2020-08-18
BR112020010815A2 (pt) 2020-11-10
CN111479817B (zh) 2023-03-21
EP3720865C0 (en) 2024-03-13
RU2020122212A3 (es) 2022-01-10
EP4385996A2 (en) 2024-06-19
US20200369707A1 (en) 2020-11-26
EP4385996A3 (en) 2024-07-31
AU2018379456B2 (en) 2022-11-24
JP2021505582A (ja) 2021-02-18
EP3720865B1 (en) 2024-03-13
CN111479817A (zh) 2020-07-31
AU2018379456A1 (en) 2020-06-25
IL275129A (en) 2020-07-30
JP7352544B2 (ja) 2023-09-28
IL275129B1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
MX2022005182A (es) Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.
EP4385996A3 (en) Novel spirobicyclic analogues
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
PH12018501099A1 (en) Novel biphenyl compound or salt thereof
MX375484B (es) Derivados de azabencimidazol como inhibidores de pi3k beta
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201990851A1 (ru) Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
TN2016000081A1 (en) Aminoheteroaryl benzamides as kinase inhibitors
MX369798B (es) Derivados macrociclicos de pirimidina.
MX2017014035A (es) Formas solidas novedosas.
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
MX2016012994A (es) Derivados de piridina macrociclicos.
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
MX382601B (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
PH12018501895A1 (en) Substituted nucleoside analogues for use as prmt5 inhibitors
MX391942B (es) Derivados de quinoxalina y piridoprazina como inhibidores de pi3k-beta
GEAP201914604A (en) Therapeutic agent for frontal lobe dysfunction
MX2019012380A (es) Cristales de compuesto piranodipiridinico.